Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $25.20.
ATXS has been the subject of several research analyst reports. TD Cowen assumed coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective for the company. Oppenheimer raised their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th.
Read Our Latest Analysis on ATXS
Institutional Inflows and Outflows
Astria Therapeutics Stock Up 1.0 %
Shares of ATXS opened at $11.18 on Friday. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90. The company has a 50-day simple moving average of $10.17 and a 200-day simple moving average of $11.34. The company has a market capitalization of $613.93 million, a PE ratio of -4.82 and a beta of 0.73.
Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). On average, research analysts anticipate that Astria Therapeutics will post -1.62 EPS for the current year.
Astria Therapeutics Company Profile
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Further Reading
- Five stocks we like better than Astria Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Dividend Payout Ratio Calculator
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Following Congress Stock Trades
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.